NCT02146378View on ClinicalTrials.gov

Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

CompletedOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

January 10, 2014

Primary Completion Date

March 10, 2023

Study Completion Date

March 10, 2023

Conditions
Transthyretin Familial Amyloid Polyneuropathy
Interventions
DRUG

Vyndaqel

20mg/day

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02146378 - Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan) | Biotech Hunter | Biotech Hunter